21 results on '"Dimopoulos, Johannes C. A."'
Search Results
2. Posttraumatic Stress Disorder After High-Dose-Rate Brachytherapy for Cervical Cancer With 2 Fractions in 1 Application Under Spinal/Epidural Anesthesia: Incidence and Risk Factors
- Author
-
Kirchheiner, Kathrin, Czajka-Pepl, Agnieszka, Ponocny-Seliger, Elisabeth, Scharbert, Gisela, Wetzel, Léonore, Nout, Remi A., Sturdza, Alina, Dimopoulos, Johannes C., Dörr, Wolfgang, and Pötter, Richard
- Published
- 2014
- Full Text
- View/download PDF
3. MRI Assessment of Cervical Cancer for Adaptive Radiotherapy
- Author
-
Dimopoulos, Johannes C. A., Schirl, Gertrude, Baldinger, Anja, Helbich, Thomas H., and Pötter, Richard
- Published
- 2009
- Full Text
- View/download PDF
4. Height Velocity and Skeletal Maturation in Elite Female Rhythmic Gymnasts
- Author
-
Georgopoulos, Neoklis A., Markou, Kostas B., Theodoropoulou, Anastasia, Vagenakis, George A., Benardot, Dan, Leglise, Michel, Dimopoulos, Johannes C. A., and Vagenakis, Apostolos G.
- Published
- 2001
5. Austria: Medical University of Vienna, Vienna.
- Author
-
Dimopoulos, Johannes C. Athanasios, Kirisits, Christian, and Pötter, Richard
- Abstract
At the Department of Radiotherapy, Medical University of Vienna 3D imaging for brachytherapy has been intensively investigated during the last decade. An open magnetic resonance image (MRI) scanner (0.2T Siemens Magnetom Open-Viva®) was installed in 1997/1998 at the division of brachytherapy in order to support image-guided brachytherapy, particularly for the treatment of gynecological cancers and prostate cancer. The MRI device was adapted to the needs of external beam radiotherapy (EBRT) and brachytherapy [1]. Specific image acquisition protocols were developed for prostate and gynecologic brachytherapy [1, 2]. At the beginning, the translation of the traditional experience based on X-ray assisted treatment planning into image-guided treatment planning was studied [3]. Finally, gynecological brachytherapy was performed MR image-guided [4, 5, 7, 10]. In cooperation with the GYN-GEC ESTRO group, concepts and terms for delineation of gross tumor volume (GTV) and clinical target volume (CTV) and organs at risk (OAR) [8], treatment plan optimization by adaptation of dwell times and locations [5, 7], integration of biological modeling [18], development of 3D image-based parameters to potentially evaluate dose volume relations for GTV and CTV as well as for OAR [9] and for dose escalation, as appropriate and feasible were developed [9, 10]. During these years, the departmental protocol for cervix cancer radiotherapy, and in particular for image-guided brachytherapy, was continuously developed [10]. Since 2001, a systematic approach, which enables prospective application of the different parameters for improvement of target coverage and dose escalation, is applied [10]. In 2007, based on the clinical experience collected during 1998–2003, the first mono-institutional study with clinical results on 145 patients treated with MR image-guided brachytherapy was published [10]. Since 2008, dose-effect relationships for the target volumes and the OARs are available for this patient series [11–14]. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
6. The Use of Sectional Imaging with CT and MRI for Image-Guided Therapy.
- Author
-
Dimopoulos, Johannes C. Athanasios and Fidarova, Elena
- Abstract
Sectional imaging with computed tomography (CT) or magnetic resonance imaging (MRI) is widely applied in modern gynecological radiotherapy. While external beam radiotherapy (EBRT) relies mainly on CT, image-guided brachytherapy (IGBT) preferably may be based on MRI. Both imaging modalities have advantages and weaknesses. The diagnostic value of sectional imaging can be improved by the use of the specific protocols for image acquisition. Image guidance enables assessment of tumor regression and interfraction organ motion with subsequent adaptation of radiotherapy treatment plans. Margin size around the tumor can be reduced and a higher tumor doses applied. This leads to an increase of locoregional control and a decrease of radiotherapy-related morbidity with improved quality of life. The potential benefits of using repetitive imaging for IGRT are the subject of ongoing and future research in gynecological radiation oncology. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
7. In Reply to Whitley et al
- Author
-
Kirchheiner, Kathrin, Czajka-Pepl, Agnieszka, Ponocny-Seliger, Elisabeth, Scharbert, Gisela, Wetzel, Léonore, Nout, Remi A., Sturdza, Alina, Dimopoulos, Johannes C., Dörr, Wolfgang, and Pötter, Richard
- Published
- 2014
- Full Text
- View/download PDF
8. Magnetic resonance imaging for assessment of parametrial tumour spread and regression patterns in adaptive cervix cancer radiotherapy.
- Author
-
Schmid, Maximilian P., Fidarova, Elena, Pötter, Richard, Petric, Primoz, Bauer, Veronika, Woehs, Veronika, Georg, Petra, Kirchheiner, Kathrin, Berger, Daniel, Kirisits, Christian, Dörr, Wolfgang, and Dimopoulos, Johannes C. A.
- Subjects
RADIOISOTOPE brachytherapy ,METASTASIS ,MAGNETIC resonance imaging ,CHI-squared test ,RESEARCH funding ,TUMOR classification ,CERVIX uteri tumors ,LOGISTIC regression analysis ,DATA analysis software ,DESCRIPTIVE statistics ,ODDS ratio ,DIAGNOSIS - Abstract
Purpose. To investigate the impact of magnetic resonance imaging (MRI)-morphologic differences in parametrial infiltration on tumour response during primary radiochemotherapy in cervical cancer. Material and methods. Eighty-five consecutive cervical cancer patients with FIGO stages IIB (n = 59) and IIIB (n = 26), treated by external beam radiotherapy (± chemotherapy) and image-guided adaptive brachytherapy, underwent T2-weighted MRI at the time of diagnosis and at the time of brachytherapy. MRI patterns of parametrial tumour infiltration at the time of diagnosis were assessed with regard to predominant morphology and maximum extent of parametrial tumour infiltration and were stratified into five tumour groups (TG): 1) expansive with spiculae; 2) expansive with spiculae and infiltrating parts; 3) infiltrative into the inner third of the parametrial space (PM); 4) infiltrative into the middle third of the PM; and 5) infiltrative into the outer third of the PM. MRI at the time of brachytherapy was used for identifying presence (residual vs. no residual disease) and signal intensity (high vs. intermediate) of residual disease within the PM. Left and right PM of each patient were evaluated separately at both time points. The impact of the TG on tumour remission status within the PM was analysed using χ
2 -test and logistic regression analysis. Results. In total, 170 PM were analysed. The TG 1, 2, 3, 4, 5 were present in 12%, 11%, 35%, 25% and 12% of the cases, respectively. Five percent of the PM were tumour-free. Residual tumour in the PM was identified in 19%, 68%, 88%, 90% and 85% of the PM for the TG 1, 2, 3, 4, and 5, respectively. The TG 3-5 had significantly higher rates of residual tumour in the PM in comparison to TG 1 + 2 (88% vs. 43%, p < 0.01). Conclusion. MRI-morphologic features of PM infiltration appear to allow for prediction of tumour response during external beam radiotherapy and chemotherapy. A predominantly infiltrative tumour spread at the time of diagnosis resulted in a significantly higher rate of residual tumour in the PM at the time of brachytherapy in comparison to a predominantly expansive tumour spread. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
9. Present status and future of high-precision image guided adaptive brachytherapy for cervix carcinoma.
- Author
-
Potter, Richard, Kirisits, Christian, Fidarova, Elena F., Dimopoulos, Johannes C. A., Berger, Daniel, Tanderup, Kari, and Lindegaard, Jacob C.
- Subjects
CERVICAL cancer treatment ,IMAGE-guided radiation therapy ,RADIOISOTOPE brachytherapy ,CANCER radiotherapy ,MAGNETIC resonance imaging - Abstract
Introduction. Image guided adaptive brachytherapy (IGABT) for cervical cancer, using mainly MRI, is an evolving method, increasingly replacing the 2D approach based on conventional radiography. During the complex 4D chain of this procedure image-assistance is provided for disease assessment, provisional treatment planning (“pre-planning”), applicator placement and reconstruction, as well as for contouring, definitive treatment planning and quality control of dose delivery. With IGABT changes of topography adjacent to the applicator, caused by tumour regression, oedema, organ changes and dilation are identified. Thus, the CTV for IGABT is primarily based on the tumour volume at the time of BT and takes into account both time and spatial domains. IGABT requires systematic concepts for target, OAR, biological modelling, DVH analysis, and dose-volume-adaptation. Methods and Results. This report focuses on the advantages and uncertainties, dose-effect relations and clinical results of the IGABT procedure addressing the current status and future perspectives. Uncertainties during the 4D chain of IGABT are mainly related to target contouring, applicator reconstruction, as well as to inter-fraction, intra-fraction and inter-application variability, as caused by tumour response and organ changes. Different from EBRT where set-up uncertainties are compensated by adding a margin to the CTV, no margins to the lateral and anterior-posterior directions can be used for IGABT. Discussion. By 3D treatment planning for IGABT significant improvement of the DVH parameters is achieved compared to 2D library plans. In small tumours the benefit is primarily obtained by a decrease of dose to nearby OAR while in large tumours the use of supplementary interstitial techniques and optimization may double the target volume that can be treated at a therapeutic dose level. The clinical impact of IGABT could recently be demonstrated by the establishment of some correlations between target- and organ-related DVH parameters versus disease control and side effects, which need further clarification. Overall, a very high local control rate can be achieved with minor treatment related morbidity. This favourable therapeutic ratio seems to be now reproducible under different conditions at various treatment centres. These results have to be validated within the upcoming multi-centre prospective IntErnational study on MRI-guided brachytherapy in locally advanced cervical cancer (EMBRACE). [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
10. Uncertainty analysis for 3D image-based cervix cancer brachytherapy by repetitive MR imaging: assessment of DVH-variations between two HDR fractions within one applicator insertion and their clinical relevance.
- Author
-
Lang S, Nesvacil N, Kirisits C, Georg P, Dimopoulos JC, Federico M, and Pötter R
- Subjects
- Female, Humans, Radiotherapy Dosage, Tumor Burden, Uncertainty, Uterine Cervical Neoplasms pathology, Brachytherapy methods, Imaging, Three-Dimensional methods, Magnetic Resonance Imaging, Interventional methods, Radiotherapy, Image-Guided methods, Uterine Cervical Neoplasms radiotherapy
- Abstract
Purpose: To investigate dosimetric uncertainties of MRI-based cervix cancer brachytherapy, when applying two HDR fractions for each applicator insertion and their clinical relevance., Methods: 21 patients with 84 MRI-examinations and fractions were investigated. After insertion of the MRI compatible tandem-ring applicator, an MRI-set was recorded and the treatment plan optimised for the first fraction. Prior to the second fraction 16-20 h later a second MRI-set was recorded, and the dose distribution from the plan of the previous day superimposed and analysed. The same procedure was repeated for fractions 3 and 4. Dose from EBRT and brachytherapy was normalised to 2 Gy-fractionation (EQD2), added up to a total dose, and compared to a calculated total dose if only 1 MRI-examination per insertion is available., Results: The total D(90) for High risk (HR) CTV was 1.2±2.7 Gy(αβ10) (1±3%) (mean±1SD) lower by individual MRI-evaluation of each fraction compared to 1 MRI per insertion. The D(2cm(3)) increased by 0.7±4.7 Gy(αβ3) (1±6%) for bladder, 1.1±2.4 Gy(αβ3) (2±4%) for rectum and decreased by 0.8±3.4 Gy(αβ3) (1±5%) for sigmoid. For HR CTV the individual approach did not identify any case with a decrease of D(90) >5 Gy(αβ10). For the bladder 3 cases, for the rectum no case and for the sigmoid 1 case was identified with an increase of D(2cm(3)) >5 Gy(αβ3). For the bladder all dose variations of more than 5 Gy(αβ3) could have been avoided by ensuring a constant bladder filling. Individual MRI-evaluation did not determine any case where dose constraints were not fulfilled., Conclusions: For the treatment schedule as applied in this study, geometric differences between applicator, target and OAR result in overall dosimetric changes, which seem to be of minor relevance in regard to clinical dose volume constraints applied at present., (Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
11. Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: dose-volume parameters and first clinical results.
- Author
-
Dimopoulos JC, Schmid MP, Fidarova E, Berger D, Kirisits C, and Pötter R
- Subjects
- Adult, Aged, Aged, 80 and over, Brachytherapy adverse effects, Feasibility Studies, Female, Humans, Middle Aged, Neoplasm Staging, Organs at Risk, Radiotherapy Dosage, Radiotherapy, Image-Guided adverse effects, Rectovaginal Fistula etiology, Survival Rate, Treatment Outcome, Tumor Burden, Vaginal Neoplasms mortality, Vaginal Neoplasms pathology, Vesicovaginal Fistula etiology, Brachytherapy methods, Chemoradiotherapy methods, Magnetic Resonance Imaging, Interventional methods, Radiotherapy, Image-Guided methods, Vaginal Neoplasms therapy
- Abstract
Purpose: To investigate the clinical feasibility of magnetic resonance image-guided adaptive brachytherapy (IGABT) for patients with locally advanced vaginal cancer and to report treatment outcomes., Methods and Materials: Thirteen patients with vaginal cancer were treated with external beam radiotherapy (45-50.4 Gy) plus IGABT with or without chemotherapy. Distribution of International Federation of Gynecology and Obstetrics stages among patients were as follows: 4 patients had Stage II cancer, 5 patients had Stage III cancer, and 4 patients had Stage IV cancer. The concept of IGABT as developed for cervix cancer was transferred and adapted for vaginal cancer, with corresponding treatment planning and reporting. Doses were converted to the equivalent dose in 2 Gy, applying the linear quadratic model (α/β = 10 Gy for tumor; α/β = 3 for organs at risk). Endpoints studied were gross tumor volume (GTV), dose-volume parameters for high-risk clinical target volume (HRCTV), and organs at risk, local control (LC), adverse side effects, and survival., Results: The mean GTV (± 1 standard deviation) at diagnosis was 45.3 (±30) cm(3), and the mean GTV at brachytherapy was 10 (±14) cm(3). The mean D90 for the HRCTV was 86 (±13) Gy. The mean D2cc for bladder, urethra, rectum, and sigmoid colon were 80 (±20) Gy, 76 (±16) Gy, 70 (±9) Gy, and 60 (±9) Gy, respectively. After a median follow-up of 43 months (range, 19-87 months), one local recurrence and two distant metastases cases were observed. Actuarial LC and overall survival rates at 3 years were 92% and 85%. One patient with Stage IVA and 1 patient with Stage III disease experienced fistulas (one vesicovaginal, one rectovaginal), and 1 patient developed periurethral necrosis., Conclusions: The concept of IGABT, originally developed for treating cervix cancer, appears to be applicable to vaginal cancer treatment with only minor adaptations. Dose-volume parameters for HRCTV and organs at risk are in a comparable range. First clinical results indicate excellent LC. Further prospective multicenter studies are needed to establish this method and to confirm these results., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
12. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy.
- Author
-
Dimopoulos JC, Petrow P, Tanderup K, Petric P, Berger D, Kirisits C, Pedersen EM, van Limbergen E, Haie-Meder C, and Pötter R
- Subjects
- Female, Humans, Imaging, Three-Dimensional, Radiotherapy Dosage, Tumor Burden, Uterine Cervical Neoplasms pathology, Brachytherapy, Magnetic Resonance Imaging, Uterine Cervical Neoplasms radiotherapy
- Abstract
The GYN GEC-ESTRO working group issued three parts of recommendations and highlighted the pivotal role of MRI for the successful implementation of 3D image-based cervical cancer brachytherapy (BT). The main advantage of MRI as an imaging modality is its superior soft tissue depiction quality. To exploit the full potential of MRI for the better ability of the radiation oncologist to make the appropriate choice for the BT application technique and to accurately define the target volumes and the organs at risk, certain MR imaging criteria have to be fulfilled. Technical requirements, patient preparation, as well as image acquisition protocols have to be tailored to the needs of 3D image-based BT. The present recommendation is focused on the general principles of MR imaging for 3D image-based BT. Methods and parameters have been developed and progressively validated from clinical experience from different institutions (IGR, Universities of Vienna, Leuven, Aarhus and Ljubljana) and successfully applied during expert meetings, contouring workshops, as well as within clinical and interobserver studies. It is useful to perform pelvic MRI scanning prior to radiotherapy ("Pre-RT-MRI examination") and at the time of BT ("BT MRI examination") with one MR imager. Both low and high-field imagers, as well as both open and close magnet configurations conform to the requirements of 3D image-based cervical cancer BT. Multiplanar (transversal, sagittal, coronal and oblique image orientation) T2-weighted images obtained with pelvic surface coils are considered as the golden standard for visualisation of the tumour and the critical organs. The use of complementary MRI sequences (e.g. contrast-enhanced T1-weighted or 3D isotropic MRI sequences) is optional. Patient preparation has to be adapted to the needs of BT intervention and MR imaging. It is recommended to visualise and interpret the MR images on dedicated DICOM-viewer workstations, which should also assist the contouring procedure. Choice of imaging parameters and BT equipment is made after taking into account aspects of interaction between imaging and applicator reconstruction, as well as those between imaging, geometry and dose calculation. In a prospective clinical context, to implement 3D image-based cervical cancer brachytherapy and to take advantage of its full potential, it is essential to successfully meet the MR imaging criteria described in the present recommendations of the GYN GEC-ESTRO working group., (Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
13. Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy.
- Author
-
Georg P, Pötter R, Georg D, Lang S, Dimopoulos JC, Sturdza AE, Berger D, Kirisits C, and Dörr W
- Subjects
- Brachytherapy methods, Cisplatin therapeutic use, Dose-Response Relationship, Radiation, Female, Humans, Linear Models, Magnetic Resonance Imaging, Interventional methods, Prospective Studies, Radiation-Sensitizing Agents therapeutic use, Radiotherapy Dosage, Brachytherapy adverse effects, Organs at Risk radiation effects, Radiation Injuries pathology, Rectum radiation effects, Urinary Bladder radiation effects, Uterine Cervical Neoplasms radiotherapy
- Abstract
Purpose: To establish dose-response relationships for late side effects of the rectum and bladder in cervix cancer patients after magnetic resonance image-guided adaptive brachytherapy (IGABT)., Methods and Materials: A cohort of 141 patients was treated with 45 to 50.4 Gy with or without cisplatin plus 4 fractions of 7 Gy IGABT. Doses for the most exposed 2, 1, and 0.1-cm(3) (D(2 cc), D(1 cc), D(0.1 cc)) volumes of the rectum and bladder were converted into the equivalent dose in 2 Gy fractions (EQD2), using a linear quadratic model (α/β = 3 Gy). Late side effects were prospectively assessed (using late effects in normal tissues subjective, objective, management and analytic [LENT SOMA]) scales. Dose-response relationships were determined by logit analyses., Results: Eleven patients developed rectal side effects, and 23 patients had urinary side effects. A significant dose effect was found for all rectal dose-volume histogram (DVH) parameters for patients with side effect grades of 1 to 4 but was only significant for D(2 cc) and D(1 cc) for grades ≥ 2. The ED10 values for D(2 cc) were 73 Gy for grades 1 to 4 and 78 Gy for grades 2 to 4 rectal morbidity. For bladder side effects, a significant dose effect was shown for all DVH parameters for complication grades ≥ 2; the respective ED10 was 101 Gy., Conclusions: Well-defined dose-response curves could be established for D(2 cc) in the rectum and the urinary bladder., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
14. Local recurrences in cervical cancer patients in the setting of image-guided brachytherapy: a comparison of spatial dose distribution within a matched-pair analysis.
- Author
-
Schmid MP, Kirisits C, Nesvacil N, Dimopoulos JC, Berger D, and Pötter R
- Subjects
- Adult, Aged, Aged, 80 and over, Biopsy, Combined Modality Therapy, Data Interpretation, Statistical, Disease Progression, Dose-Response Relationship, Radiation, Endpoint Determination, Female, Humans, Middle Aged, Neoplasm Staging, Radiotherapy Dosage, Risk Factors, Treatment Outcome, Uterine Cervical Neoplasms drug therapy, Brachytherapy methods, Magnetic Resonance Imaging, Interventional, Neoplasm Recurrence, Local pathology, Radiography, Interventional, Radiotherapy Planning, Computer-Assisted methods, Tomography, X-Ray Computed, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms radiotherapy
- Abstract
Purpose: It has been shown that a cumulative dose of ≥87 Gy (EQD2) of external beam radiotherapy (EBRT) and image guided adaptive brachytherapy (IGABT) to the high risk clinical target volume (HR CTV) confer a local control rate >95% in locally advanced cervical cancer. This study examines the dose distribution within the HR CTV and intermediate (IR) CTV in patients with cervical cancer treated with definitive EBRT +/- concomitant chemotherapy and MRI-based IGABT between patients with local recurrence (LR) and patients in continuous complete local remission (CCLR)., Material and Methods: From 1998 to 2010, 265 patients were treated with definitive EBRT +/- concomitant chemotherapy and IGABT. Twenty-four LRs were documented. For the statistical analysis all patients with LR were matched to patients in CCLR from our database according to the following criteria: FIGO stage, histology, lymph node status, tumour size and chemotherapy. DVH parameters (D50, D90, D98, D100) were reported for HR CTV and IR CTV. In order to report the minimum dose in the region where the recurrence occurred, the HR CTV/IR CTV were divided into four quadrants on transversal planes. The minimum dose at the HR CTV/IR CTV contour was measured (within the corresponding quadrant closest to the LR) in the treatment planning system. A mean minimum point dose (MPD) was calculated by averaging these measurements on four consecutive slices at the level of the recurrence for each of the 4 brachytherapy fractions. EQD2 doses were calculated by summation of all BT and external beam therapy fractions. For each matched patient in the control group the measurements were performed on the same quadrant and at the same level., Results: Sufficient image data were available for 21 LRs. Eight central failures and 13 non-central failures were observed. The mean D90 and D100 for HR CTV were 77 Gy and 61 Gy for patients with LR and 95 Gy and 71 Gy for patients in CCLR, respectively (p<0.01). The MPD for HR CTV was 72 Gy for patients in the LR arm and 99 Gy for patients in the CCLR arm (p<0.01). In the LR arm seven patients had a D90 for HR CTV ≥87 Gy, however, in only three patients the MPD was ≥87 Gy., Conclusion: This study demonstrated significant differences in local outcome according to the delivered dose. In 85% of the LRs systematic low dose regions with less than 87 Gy were found at HR CTV contour. Systematic low dose regions leading to local recurrence could be detected even if a D90 HR CTV ≥87 Gy was applied. In addition to DVH parameters, inspection of the spatial dose distribution remains a key point in dose prescription., (Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
15. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer.
- Author
-
Pötter R, Georg P, Dimopoulos JC, Grimm M, Berger D, Nesvacil N, Georg D, Schmid MP, Reinthaller A, Sturdza A, and Kirisits C
- Subjects
- Chemoradiotherapy, Female, Humans, Magnetic Resonance Imaging, Middle Aged, Neoplasm Staging, Radiotherapy Dosage, Treatment Outcome, Uterine Cervical Neoplasms drug therapy, Uterine Cervical Neoplasms pathology, Brachytherapy adverse effects, Radiotherapy, Conformal adverse effects, Uterine Cervical Neoplasms radiotherapy
- Abstract
Background: To analyse the overall clinical outcome and benefits by applying protocol based image guided adaptive brachytherapy combined with 3D conformal external beam radiotherapy (EBRT)±chemotherapy (ChT)., Methods: Treatment schedule was EBRT with 45-50.4Gy±concomitant cisplatin chemotherapy plus 4×7Gy High Dose Rate (HDR) brachytherapy. Patients were treated in the "protocol period" (2001-2008) with the prospective application of the High Risk CTV concept (D90) and dose volume constraints for organs at risk including biological modelling. Dose volume adaptation was performed with the aim of dose escalation in large tumours (prescribed D90>85Gy), often with inserting additional interstitial needles. Dose volume constraints (D(2cc)) were 70-75Gy for rectum and sigmoid and 90Gy for bladder. Late morbidity was prospectively scored, using LENT/SOMA Score. Disease outcome and treatment related late morbidity were evaluated and compared using actuarial analysis., Findings: One hundred and fifty-six consecutive patients (median age 58years) with cervix cancer FIGO stages IB-IVA were treated with definitive radiotherapy in curative intent. Histology was squamous cell cancer in 134 patients (86%), tumour size was >5cm in 103 patients (66%), lymph node involvement in 75 patients (48%). Median follow-up was 42months for all patients. Interstitial techniques were used in addition to intracavitary brachytherapy in 69/156 (44%) patients. Total prescribed mean dose (D90) was 93±13Gy, D(2cc) 86±17Gy for bladder, 65±9Gy for rectum and 64±9Gy for sigmoid. Complete remission was achieved in 151/156 patients (97%). Overall local control at 3years was 95%; 98% for tumours 2-5cm, and 92% for tumours >5cm (p=0.04), 100% for IB, 96% for IIB, 86% for IIIB. Cancer specific survival at 3years was overall 74%, 83% for tumours 2-5cm, 70% for tumours >5cm, 83% for IB, 84% for IIB, 52% for IIIB. Overall survival at 3years was in total 68%, 72% for tumours 2-5cm, 65% for tumours >5cm, 74% for IB, 78% for IIB, 45% for IIIB. In regard to late morbidity in total 188 grade 1+2 and 11 grade 3+4 late events were observed in 143 patients. G1+2/G3+4 events for bladder were n=32/3, for rectum n=14/5, for bowel (including sigmoid) n=3/0, for vagina n=128/2, respectively., Interpretation: 3D conformal radiotherapy±chemotherapy plus image (MRI) guided adaptive intracavitary brachytherapy including needle insertion in advanced disease results in local control rates of 95-100% at 3years in limited/favourable (IB/IIB) and 85-90% in large/poor response (IIB/III/IV) cervix cancer patients associated with a moderate rate of treatment related morbidity. Compared to the historical Vienna series there is relative reduction in pelvic recurrence by 65-70% and reduction in major morbidity. The local control improvement seems to have impact on CSS and OS. Prospective clinical multi-centre studies are mandatory to evaluate these challenging mono-institutional findings., (Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
16. Dose-volume histogram parameters and late side effects in magnetic resonance image-guided adaptive cervical cancer brachytherapy.
- Author
-
Georg P, Lang S, Dimopoulos JC, Dörr W, Sturdza AE, Berger D, Georg D, Kirisits C, and Pötter R
- Subjects
- Adult, Aged, Aged, 80 and over, Brachytherapy methods, Female, Follow-Up Studies, Humans, Magnetic Resonance Imaging, Middle Aged, Organs at Risk radiation effects, Prospective Studies, Radiotherapy Dosage, Tumor Burden, Uterine Cervical Neoplasms pathology, Brachytherapy adverse effects, Colon, Sigmoid radiation effects, Radiation Injuries diagnosis, Radiotherapy, Conformal adverse effects, Rectum radiation effects, Urinary Bladder radiation effects, Uterine Cervical Neoplasms radiotherapy
- Abstract
Purpose: To evaluate the predictive value of dose-volume histogram (DVH) parameters for late side effects of the rectum, sigmoid colon, and bladder in image-guided brachytherapy for cervix cancer patients., Methods and Materials: A total of 141 patients received external-beam radiotherapy and image-guided brachytherapy with or without chemotherapy. The DVH parameters for the most exposed 2, 1, and 0.1 cm(3) (D(2cc), D(1cc), and D(0.1cc)) of the rectum, sigmoid, and bladder, as well as International Commission on Radiation Units and Measurements point doses (D(ICRU)) were computed. Total doses were converted to equivalent doses in 2 Gy by applying the linear-quadratic model (α/β = 3 Gy). Late side effects were prospectively assessed using the Late Effects in Normal Tissues-Subjective, Objective, Management and Analytic score. The following patient groups were defined: Group 1: no side effects (Grade 0); Group 2: side effects (Grade 1-4); Group 3: minor side effects (Grade 0-1); and Group 4: major side effects (Grade 2-4)., Results: The median follow-up was 51 months. The overall 5-year actuarial side effect rates were 12% for rectum, 3% for sigmoid, and 23% for bladder. The mean total D(2cc) were 65 ± 12 Gy for rectum, 62 ± 12 Gy for sigmoid, and 95 ± 22 Gy for bladder. For rectum, statistically significant differences were observed between Groups 1 and 2 in all DVH parameters and D(ICRU). Between Groups 3 and 4, no difference was observed for D(0.1cc). For sigmoid, significant differences were observed for D(2cc) and D(1cc), but not for D(0.1cc) in all groups. For bladder, significant differences were observed for all DVH parameters only comparing Groups 3 and 4. No differences were observed for D(ICRU)., Conclusions: The parameters D(2cc) and D(1cc) have a good predictive value for rectal toxicity. For sigmoid, no prediction could be postulated because of limited data. In bladder, DVH parameters were predictive only for major toxicity., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
17. Dose-effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapy.
- Author
-
Dimopoulos JC, Pötter R, Lang S, Fidarova E, Georg P, Dörr W, and Kirisits C
- Subjects
- Adult, Aged, Aged, 80 and over, Dose-Response Relationship, Radiation, Female, Humans, Middle Aged, Uterine Cervical Neoplasms pathology, Brachytherapy methods, Magnetic Resonance Imaging methods, Uterine Cervical Neoplasms radiotherapy
- Abstract
Background and Purpose: To analyse dose-response relationships for local control of cervical cancer after MR image-guided brachytherapy (IGBT) based on dose-volume histogram parameters., Methods and Materials: The analysis includes 141 patients with cervix cancer (stages IB-IVA) treated with 45-50.4 Gy EBRT+/-cisplatin plus 4 x 7 Gy IGBT. Gross tumour volume (GTV), high risk clinical target volume (HR CTV) and intermediate risk CTV (IR CTV) were delineated and DVH parameters (D90, D100) were assessed. Doses were converted to the equivalent dose in 2 Gy (EQD2) using linear-quadratic model (alpha/beta=10 Gy). Groups of patients were formed according to tumour size at diagnosis (GTV(D)) of 2-5 cm (group 1) or >5 cm (2), with subgroups of the latter for HR CTV size at first IGBT 2-5 cm (2a) or >5 cm (2b). Dose-response dependence for local recurrence was evaluated by logit analysis., Results: Eighteen local recurrences in the true pelvis were observed. Dose-response analyses revealed a significant effect of HR CTV D100 (p=0.02) and D90 (p=0.005). The ED50-values for tumour control were 33+/-15 Gy (D100) and 45+/-19 Gy (D90). ED90-values were 67 Gy (95% confidence interval [50;104]) and 86 Gy [77;113], respectively., Conclusions: A significant dependence of local control on D100 and D90 for HR CTV was found. Tumour control rates of >90% can be expected at doses >67 Gy and 86 Gy, respectively.
- Published
- 2009
- Full Text
- View/download PDF
18. Dose-volume histogram parameters and local tumor control in magnetic resonance image-guided cervical cancer brachytherapy.
- Author
-
Dimopoulos JC, Lang S, Kirisits C, Fidarova EF, Berger D, Georg P, Dörr W, and Pötter R
- Subjects
- Adenocarcinoma pathology, Adenocarcinoma radiotherapy, Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell radiotherapy, Female, Follow-Up Studies, Humans, Linear Models, Magnetic Resonance Imaging, Middle Aged, Multivariate Analysis, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local radiotherapy, Neoplasm Staging, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted methods, Brachytherapy methods, Magnetic Resonance Imaging, Interventional methods, Tumor Burden, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms radiotherapy
- Abstract
Purpose: To investigate the value of dose-volume histogram (DVH) parameters for predicting local control in magnetic resonance (MR) image-guided brachytherapy (IGBT) for patients with cervical cancer., Methods and Materials: Our study population consists of 141 patients with cervical cancer (Stages IB-IVA) treated with 45-50 Gy external beam radiotherapy plus four times 7 Gy IGBT with or without cisplatin. Gross tumor volume (GTV), high-risk clinical target volume (HRCTV), and intermediate-risk clinical target volume (IRCTV) were contoured, and DVH parameters (minimum dose delivered to 90% of the volume of interest [D90] and D100) were assessed. Doses were converted to the equivalent dose in 2 Gy (EQD2) by applying the linear quadratic model (alpha/beta = 10 Gy). Groups were defined for patients with or without local recurrence (LR) in the true pelvis for tumor size at diagnosis (GTV at diagnosis [GTVD] of 2-5 cm (Group 1) or greater than 5 cm (Group 2) and for tumor size response at IGBT (HRCTV) of 2-5 cm (Group 2a) or greater than 5 cm (Group 2b)., Results: Eighteen LRs were observed. The most important DVH parameters correlated with LR were the D90 and D100 for HRCTV. Mean D90 and D100 values for HRCTV were 86 +/- 16 and 65 +/- 10 Gy, respectively. The D90 for HRCTV greater than 87 Gy resulted in an LR incidence of 4% (3 of 68) compared with 20% (15 of 73) for D90 less than 87 Gy. The effect was most pronounced in the tumor group (Group 2b)., Conclusions: We showed an increase in local control in IGBT in patients with cervical cancer with the dose delivered, which can be expressed by the D90 and D100 for HRCTV. Local control rates greater than 95% can be achieved if the D90 (EQD2) for HRCTV is 87 Gy or greater.
- Published
- 2009
- Full Text
- View/download PDF
19. Inter-observer comparison of target delineation for MRI-assisted cervical cancer brachytherapy: application of the GYN GEC-ESTRO recommendations.
- Author
-
Dimopoulos JC, De Vos V, Berger D, Petric P, Dumas I, Kirisits C, Shenfield CB, Haie-Meder C, and Pötter R
- Subjects
- Adult, Aged, Female, Humans, Middle Aged, Observer Variation, Brachytherapy methods, Magnetic Resonance Imaging methods, Uterine Cervical Neoplasms radiotherapy
- Abstract
Background and Purpose: To investigate the inter-observer variation of target contouring when using the GYN GEC-ESTRO recommendations for MR image-guided brachytherapy (IGBT) for cervical cancer., Materials and Methods: Nineteen cervical cancer patients, treated by radiotherapy at the Institut Gustave Roussy (IGR) in France (n=9) or at the Medical University of Vienna (AKH) in Austria (n=10) were included in this study. IGBT was used for all patients. Two radiation oncologists, one from IGR and the other from AKH, outlined the target volumes on MRI at the time of brachytherapy according to the GYN GEC-ESTRO recommendations. The absolute, common and encompassing volumes and their conformity indices (CIs) were assessed for the GTV, HR CTV and IR CTV. D90 and D100 for each volume were assessed. Visual evaluation was made to assess the reasons for the most frequent inter-observer differences., Results: The mean volumes of GTV and HR CTV did not differ significantly between the observers, p>0.05. Significant differences were observed only for the mean volumes of the IR CTV of both centres, p<0.05. CIs ranged from 0.5 to 0.7. DVH-parameter analyses did not reveal any statistical differences, except for the D100 for the GTV at AKH, and the D90 for the IR CTV at IGR, p<0.05. Underlying reasons for inter-observer differences included image contrast adjustment and neglecting to consider anatomical borders., Conclusions: The results of this inter-observer study show that the application of the GYN GEC-ESTRO recommendations for IGBT contouring at two different institutions with two different traditions for applicators, CTV assessment, MR image acquisition and dose prescription is feasible, and it produces acceptable inter-observer variability.
- Published
- 2009
- Full Text
- View/download PDF
20. The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: clinical feasibility and preliminary results.
- Author
-
Dimopoulos JC, Kirisits C, Petric P, Georg P, Lang S, Berger D, and Pötter R
- Subjects
- Adult, Aged, Aged, 80 and over, Brachytherapy methods, Carcinoma, Squamous Cell secondary, Feasibility Studies, Female, Humans, Magnetic Resonance Imaging, Middle Aged, Radiotherapy Dosage, Radiotherapy, Conformal, Treatment Outcome, Uterine Cervical Neoplasms pathology, Brachytherapy instrumentation, Carcinoma, Squamous Cell radiotherapy, Uterine Cervical Neoplasms radiotherapy
- Abstract
Purpose: The aims of this study were to investigate the clinical feasibility and to report on preliminary treatment outcomes of combined intracavitary/interstitial brachytherapy, using a novel applicator and magnetic resonance imaging (MRI)-based treatment planning in patients with locally advanced cervical cancer., Methods and Materials: A total of 22 cervical cancer patients with insufficient response and/or unfavorable topography after external-beam irradiation were included in this study. Parametrial extent of the disease in these patients was judged to exceed the coverage limit of intracavitary brachytherapy alone. A modified tandem/ring (T/R) applicator for guidance of parametrial needles (N) was used to perform high-dose-rate-brachytherapy with MRI-based treatment planning. Clinical feasibility and preliminary treatment outcomes were assessed., Results: A total of 44 interstitial needle implants were performed. The spatial relations between the T/R + N applicator, high-risk clinical target volume, and organs at risk were visible clearly in all cases. Accurate and reproducible needle placement could be achieved in the majority of cases. No severe adverse events were caused by the intervention. The mean follow-up period was 20 months (range, 5-35 months). No G3 to G4 early or persistent late side effects were observed. Complete remission was achieved in 21 patients (95%). One local recurrence was observed within the high-risk clinical target volume area during follow-up., Conclusions: Our preliminary clinical experience indicates that combined intracavitary and interstitial MRI-based brachytherapy in patients with significant residual disease after external-beam therapy extending up to the distal third of parametria is feasible and allows excellent local control and a low rate of morbidity.
- Published
- 2006
- Full Text
- View/download PDF
21. Systematic evaluation of MRI findings in different stages of treatment of cervical cancer: potential of MRI on delineation of target, pathoanatomic structures, and organs at risk.
- Author
-
Dimopoulos JC, Schard G, Berger D, Lang S, Goldner G, Helbich T, and Pötter R
- Subjects
- Adult, Aged, Colon, Sigmoid anatomy & histology, Female, Humans, Middle Aged, Urinary Bladder anatomy & histology, Brachytherapy, Magnetic Resonance Imaging, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms radiotherapy
- Abstract
Purpose: To compare magnetic resonance imaging (MRI) findings at different stages of cervix cancer treatment and to define the potential of MRI to delineate the gross tumor volume (GTV), clinical target volume (CTV), pathoanatomic structures, and organs at risk (OAR) in brachytherapy., Methods and Materials: Forty-nine patients underwent MRI at diagnosis and at brachytherapy. The ability to discriminate anatomic structures on MRI was assessed (quality factor: 0 = inability to discriminate; 1 = fair discrimination; 2 = good discrimination; 3 = excellent discrimination). The overall ability to visualize (percentage of patients with quality factors greater than 0) and the overall discrimination quality score (mean quality factors of all patients) were estimated for the applicator, GTV at diagnosis (GTV(D)), GTV at brachytherapy (GTV(BT))/"gray zones," cervix rim/uterine corpus, OAR, vaginal wall, and parametria., Results: The overall ability to visualize the applicator on MRI at brachytherapy was 100%; for the GTV(BT)/"gray zones," cervix rim/uterine corpus, OAR, and vaginal wall, visualization was 98% (overall discrimination quality factors: 1.2, 2.9, 2.1, 1.9, 1.7, and 2.6). Three of 4 borders of parametrial space were defined in more than 98% (discrimination quality factors: 2.9, 2.1, and 1.2)., Conclusion: Magnetic resonance imaging provides appropriate information for definition of the applicator, GTV, CTV, pathoanatomic structures, and OAR that enables precise delineation for cervix cancer brachytherapy.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.